Company Filing History:
Years Active: 2010-2015
Title: Innovations of Jong Tae Kim in Gastric Cancer Research
Introduction
Jong Tae Kim is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of biomedical research, particularly in the diagnosis and treatment of gastric cancer. With a total of 2 patents, his work focuses on identifying biomarkers and developing diagnostic tools that can aid in the early detection of this disease.
Latest Patents
Among his latest patents, Jong Tae Kim has developed innovative methods involving CST1, DCC1, IFITM1, and MELK as markers for diagnosing stomach cancer. The invention relates to a diagnostic composition that measures the expression levels of these biomarkers. This includes a kit for detecting the markers and a method for screening therapeutic agents for gastric cancer. Another significant patent involves a monoclonal antibody specific for the N-myc downstream regulated gene 2 (NDRG 2) protein. This invention encompasses a cell line producing the monoclonal antibody, a method for measuring the quantity and quality of NDRG 2 protein, and a protein chip utilizing this technology. The NDRG 2 protein is specifically expressed in dendritic cells differentiated from human peripheral blood monocytes, which can be crucial for cancer research and treatment.
Career Highlights
Jong Tae Kim is affiliated with the Korea Research Institute of Bioscience and Biotechnology. His work at this esteemed institution has allowed him to focus on groundbreaking research that has the potential to impact clinical practices in oncology.
Collaborations
He has collaborated with notable colleagues, including Hee Gu Lee and Eun Young Song, to advance his research initiatives. Their combined expertise contributes to the innovative approaches being developed in the field of cancer diagnostics.
Conclusion
Jong Tae Kim's contributions to gastric cancer research through his patents and collaborations highlight the importance of innovation in medical science. His work not only enhances our understanding of cancer biomarkers but also paves the way for improved diagnostic and therapeutic strategies.